Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

医学 队列 内科学 肿瘤科 无进展生存期 单变量分析 肺癌 外科肿瘤学 性能状态 贝伐单抗 外科 癌症 化疗 多元分析
作者
Ziyi Xu,Xuezhi Hao,Qi Wang,Ke Yang,Junling Li,Puyuan Xing
出处
期刊:BMC Cancer [BioMed Central]
卷期号:23 (1): 206-206 被引量:23
标识
DOI:10.1186/s12885-023-10676-x
摘要

OBJECTIVES: Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with poor outcomes. In this study, we evaluated the efficacy of single-agent furmonertinib 160 mg or combining with anti-angiogenic agent in NSCLC patients who had developed BM/LM progression from previous tyrosine kinase inhibior (TKI) treatment. METHODS: EGFR-mutated NSCLC patients who developed BM (the BM cohort) or LM progression (the LM cohort) were included, having received furmonertinib 160 mg daily as second-line or later treatment, with or without anti-angiogenic agents. The intracranial efficacy was evaluated by intracranial progression-free survival (iPFS). RESULTS: Totally 12 patients in the BM cohort and 16 patients in the LM cohort were included. Almost one half of patients in the BM cohort and a majority in the LM cohort had a poor physical status, with a Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥2. The administration of single-agent furmonertinib or combination treatment achieved a median iPFS of 3.6 months (95%CI 1.435-5.705) in the BM cohort, and 4.3 months (95%CI 2.094-6.486) in the LM cohort. Subgroup and univariate analysis has shown that a good ECOG-PS correlated with a favorable efficacy of furmonertinib in the BM cohort (median iPFS = 2.1 with ECOG-PS ≥ 2 vs. 14.6 months with ECOG-PS < 2, P < 0.05). Overall, any grade of adverse events (AEs) occured in 46.4% of patients (13/28). Among them, 14.3% of patients (4 of 28) had grade 3 or higher AEs, and were all under control, led to no dose reductions or suspension. CONCLUSION: Single-agent furmonertinib 160 mg or in combination of anti-angiogenic agent is an optional salvage therapy for advanced NSCLC patients who developed BM/LM progression from prior EGFR-TKI treatment, with a promising efficacy and an acceptable safety profile, and is worth of further exploration.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Code_king发布了新的文献求助10
刚刚
Code_king发布了新的文献求助10
刚刚
华仔的应助被三花花花采纳,获得20
刚刚
dun完成签到,获得积分10
1秒前
锦2004发布了新的文献求助10
1秒前
1秒前
Code_king发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
乐铭完成签到 ,获得积分10
1秒前
1秒前
congcong发布了新的文献求助20
1秒前
2秒前
安静的颖发布了新的文献求助10
2秒前
共享精神的应助被月月采纳,获得10
3秒前
淡泊宁静发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
积极努力发布了新的文献求助30
3秒前
杨柳依依关注了科研通微信公众号
3秒前
4秒前
4秒前
爱吃小笼包完成签到,获得积分10
4秒前
5秒前
果果发布了新的文献求助10
5秒前
5秒前
ParkMoonJ的应助被MooN采纳,获得10
5秒前
猪猪hero发布了新的文献求助10
5秒前
6秒前
judy007完成签到,获得积分10
6秒前
Llh完成签到,获得积分20
6秒前
adam完成签到,获得积分20
6秒前
哇哦哇哦嗷哦完成签到,获得积分10
6秒前
文章大发发布了新的文献求助10
7秒前
炙热蘑菇完成签到 ,获得积分10
7秒前
蚕豆主播发布了新的文献求助10
7秒前
要减肥鸣凤完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695